Carrie Bourdow
Chief Executive Officer en TREVENA, INC. .
Fortuna: 43 442 $ al 31/03/2024
Cargos activos de Carrie Bourdow
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| TREVENA, INC. | Chief Executive Officer | 01/10/2018 | - |
| Chairman | 01/01/2024 | - | |
| President | 01/10/2018 | - | |
| Director/Board Member | 01/10/2018 | 01/01/2024 | |
| Chief Operating Officer | 02/02/2018 | 01/10/2018 | |
| Corporate Officer/Principal | 04/05/2015 | 02/02/2018 |
Historial de carrera de Carrie Bourdow
Antiguos cargos conocidos de Carrie Bourdow.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| NABRIVA THERAPEUTICS PLC | Director/Board Member | 23/06/2017 | 30/07/2023 |
| Independent Dir/Board Member | 23/06/2017 | 30/07/2023 | |
| CARISMA THERAPEUTICS, INC. | Director/Board Member | 20/02/2020 | 07/03/2023 |
| Independent Dir/Board Member | 20/02/2020 | 07/03/2023 | |
| CUBIST PHARMACEUTICALS INC | Sales & Marketing | 01/05/2013 | 01/05/2015 |
Formación de Carrie Bourdow.
| Hendrix College | Undergraduate Degree |
| Southern Illinois University | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 6 |
| Irlanda | 2 |
Operativa
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
| Chief Executive Officer | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| TREVENA, INC. | Health Technology |
| NABRIVA THERAPEUTICS PLC | Health Technology |
| Empresas privadas | 2 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Carrie Bourdow
- Experiencia
